Short Supply of Quinolone Antibiotic

FDA Approves Lucentis for Diabetic Retinopathy With Diabetic Macular Edema
FDA Approves Lucentis for Diabetic Retinopathy With Diabetic Macular Edema
The Food and Drug Administration (FDA) announced that Factive (gemifloxacin mesylate; LG Life Sciences) is currently in shortage.

The Food and Drug Administration (FDA) announced that Factive (gemifloxacin mesylate; LG Life Sciences) is currently in shortage.

Factive 320mg tablets in 5- and 7-count blister packs are currently in shortage due to a legal dispute regarding license to manufacture and distribute the drug. There is currently no estimated duration of the shortage.

Factive is a quinolone antibiotic indicated for the treatment of susceptible infections including acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia in adults aged ≥18 years.

For more information call For more information call (888) 463-6332 or visit FDA.gov.

This article originally appeared on MPR